Welcome to the RWT Staff Publications Repository
The repository contains the records of published and unpublished research authored by NHS staff working for the Royal Wolverhampton NHS Trust and its partners. The repository is managed by the Library and Knowledge Services of the Trust and supported by the Non-Medical Research Leads Network Group and the Research and Development Directorate.
If you are a member of RWT staff and you would like to submit an item to the repository, please fill in this online form.
If you have a list of publications you'd like to submit, please e-mail the repository firstname.lastname@example.org admin team.
Communities in RWT Staff Repository
Select a community to browse its collections.
(Clinical Rheumatology, Springer Nature, 2021-10-30)Long-term sequel of acute COVID-19, commonly referred to as long COVID, has affected millions of patients worldwide. Long COVID patients display persistent or relapsing and remitting symptoms that include fatigue, ...
(The Royal Wolverhampton NHS Trust, 2021-11-24)The General Medical Council (GMC) expects all newly qualified doctors are able to safely and effectively perform a mandated list of practical skills and procedures. The medical students from the University of Birmingham ...
Utilising digital health services to enable clinical placement expansion in a cardiac rehabilitation service. (The Royal Wolverhampton NHS Trust, 2021-11-05)HEI’s are under more pressure than ever to find placement capacity for students. This was made increasingly difficult during the COVID-19 pandemic, with many services having to change the way they offer services. Therefore ...
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. (The Lancet Oncology, Elsevier, 2021-11-01)Background: Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and ...
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. (The Lancet Oncology, Elsevier, 2021-11-01)Background: In the primary analysis of the phase 3 MAIA trial (median follow-up 28·0 months), a significant improvement in progression-free survival was observed with daratumumab plus lenalidomide and dexamethasone versus ...